Timberlyne Therapeutics
Privately held: no public share price
Assets
(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | CD38Monoclonal antibody | Multiple Myeloma |
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (3)
2030 (1)
May 2030 (1)
Est. primary completion 2030-05 · NCT07910903 · CT.gov ↗
What to watch
Financial reports
No financial reports recorded.